Lomitapide: Targeting METTL3 to Overcome Osimertinib Resistance in NSCLC Through Autophagy Activation

Abstract

Osimertinib resistance remains a significant challenge in the treatment of non-small cell lung cancer (NSCLC). N⁶-methyladenosine (m⁶A) modifications are closely linked to various mechanisms of anticancer resistance and autophagy, offering new avenues for targeted therapies. However, the role of m⁶A-mediated autophagy in osimertinib-resistant NSCLC is still unclear. In this study, we utilized multi-omics sequencing analysis and found that overexpression of the m⁶A methyltransferase METTL3 contributes to osimertinib resistance in NSCLC. Importantly, we identified that METTL3 positively regulates the expression of the autophagy-related gene ubiquinone-cytochrome C reductase complex assembly factor 2 (UQCC2) through an m⁶A-dependent mechanism. Further, we confirmed that METTL3 knockdown leads to UQCC2 downregulation and triggers autophagy activation. Interestingly, lomitapide, a cholesterol-lowering drug, was repurposed to enhance the sensitivity of cancer cells to therapy by inhibiting METTL3, which in turn activated autophagy-associated cell death pathways, reversing osimertinib resistance. This study emphasizes the critical role of the METTL3/UQCC2 axis in autophagy-mediated drug resistance and positions lomitapide as a promising METTL3 inhibitor and autophagy inducer with potential therapeutic effects, either alone or in combination with other anticancer agents, in patients with osimertinib-resistant NSCLC.

Keywords

autophagy / lomitapide / N6-methyladenosine (m6A) modifications / non-small cell lung cancer / osimertinib resistance

References

[1] R. L.Siegel, A. N.Giaquinto, and A.Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024):12–49.

[2] D. A.Haber, D. W.Bell, R.Sordella, et al., “Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors,” Cold Spring Harbor Symposia on Quantitative Biology 70 (2005):419–426.

[3] J. P.Robichaux, X.Le, R. S. K.Vijayan, et al., “Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC,” Nature 597, no. 7878 (2021):732–737.

[4] P. A.Jänne, J. C. H. Yang, D. W.Kim, et al., “AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer,” New England Journal of Medicine 372, no. 18 (2015):1689–1699.

[5] A.Noronha, N.Belugali Nataraj, J. S.Lee, et al., “AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer,” Cancer Discovery 12, no. 11 (2022):2666–2683.

[6] J. C.Madukwe, “Overcoming Drug Resistance in Cancer,” Cell 186, no. 8 (2023):1515–1516.

[7] K.Fu, F.Xie, F.Wang, and L. Fu, “Therapeutic Strategies for EGFR-Mutated Non-Small Cell Lung Cancer Patients With Osimertinib Resistance,” Journal of Hematology &Oncology 15, no. 1 (2022):173.

[8] L.Galluzzi and D. R. Green, “Autophagy-Independent Functions of the Autophagy Machinery,” Cell 177, no. 7 (2019):1682–1699.

[9] B.Levine and G.Kroemer, “Biological Functions of Autophagy Genes: A Disease Perspective,” Cell 176, no. 1–2 (2019):11–42.

[10] G.Liang, Y.Ling, M.Mehrpour, et al., “Autophagy-Associated Circrna Circcdyl Augments Autophagy and Promotes Breast Cancer Progression,” Molecular Cancer 19, no. 1 (2020):65.

[11] Y.Xing, X.Wei, Y.Liu, et al., “Autophagy Inhibition Mediated by MCOLN1/TRPML1 Suppresses Cancer Metastasis via Regulating a ROS-Driven TP53/p53 Pathway,” Autophagy 18, no. 8 (2022):1932–1954.

[12] L.Xi, M.Peng, S.Liu, et al., “Hypoxia-Stimulated ATM Activation Regulates Autophagy-Associated Exosome Release From Cancer-Associated Fibroblasts to Promote Cancer Cell Invasion,” Journal of Extracellular Vesicles 10, no. 11 (2021):e12146.

[13] J. H.Han, Y. K.Kim, H.Kim, et al., “Snail Acetylation by Autophagy-Derived Acetyl-Coenzyme A Promotes Invasion and Metastasis of KRAS-LKB1 Co-Mutated Lung Cancer Cells,” Cancer Communications 42, no. 8 (2022):716–749.

[14] Y.Qin, M.Ashrafizadeh, V.Mongiardini, et al., “Autophagy and Cancer Drug Resistance in Dialogue: Pre-Clinical and Clinical Evidence,” Cancer Letters 570 (2023):216307.

[15] T.Yu, F.Guo, Y.Yu, et al., “Fusobacterium Nucleatum Promotes Chemoresistance to Colorectal Cancer by Modulating Autophagy,” Cell 170, no. 3 (2017):548–563.e16.

[16] X.Li, S.He, and B.Ma, “Autophagy and Autophagy-Related Proteins in Cancer,” Molecular Cancer 19, no. 1 (2020):12.

[17] A. J.Wagner, V.Ravi, R. F.Riedel, et al., “nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors,” Journal of Clinical Oncology 39, no. 33 (2021):3660–3670.

[18] J. J.Harding, A.Awada, G.Roth, et al., “First-in-Human Effects of PPT1 Inhibition Using the Oral Treatment With GNS561/Ezurpimtrostat in Patients With Primary and Secondary Liver Cancers,” Liver Cancer 11, no. 3 (2022):268–277.

[19] H.Maes, N.Rubio, A. D.Garg, and P. Agostinis, “Autophagy: Shaping the Tumor Microenvironment and Therapeutic Response,” Trends in Molecular Medicine 19, no. 7 (2013):428–446.

[20] E.Bestion, E.Raymond, S.Mezouar, and P.Halfon, “Update on Autophagy Inhibitors in Cancer: Opening up to a Therapeutic Combination With Immune Checkpoint Inhibitors,” Cells 12, no. 13 (2023):1702.

[21] L.Li, Y.Wang, L.Jiao, et al., “Protective Autophagy Decreases Osimertinib Cytotoxicity Through Regulation of Stem Cell-Like Properties in Lung Cancer,” Cancer Letters 452 (2019):191–202.

[22] X.Wang, Z.Lu, A.Gomez, et al., “N6-Methyladenosine-Dependent Regulation of Messenger RNA Stability,” Nature 505, no. 7481 (2014):117–120.

[23] J. M.Fustin, M.Doi, Y.Yamaguchi, et al., “RNA-Methylation-Dependent RNA Processing Controls the Speed of the Circadian Clock,” Cell 155, no. 4 (2013):793–806.

[24] X.Jiang, B.Liu, Z.Nie, et al., “The Role of m6A Modification in the Biological Functions and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021):74.

[25] H.Yin, X.Zhang, P.Yang, et al., “RNA m6A Methylation Orchestrates Cancer Growth and Metastasis via Macrophage Reprogramming,” Nature Communications 12, no. 1 (2021):1394.

[26] L.Zhang, Y.Wan, Z.Zhang, et al., “IGF2BP1 Overexpression Stabilizes PEG10 mRNA in an m6A-Dependent Manner and Promotes Endometrial Cancer Progression,” Theranostics 11, no. 3 (2021):1100–1114.

[27] J.Wang, H.Yu, W.Dong, et al., “N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells’Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways,” Gastroenterology 164, no. 6 (2023):990–1005.

[28] Z.Lin, Y.Niu, A.Wan, et al., “RNA m(6) A Methylation Regulates Sorafenib Resistance in Liver Cancer Through FOXO3-Mediated Autophagy,” EMBO Journal 39, no. 12 (2020):e103181.

[29] H.Chen, Y.Xiang, Y.Yin, et al., “The m6A Methyltransferase METTL3 Regulates Autophagy and Sensitivity to Cisplatin by Targeting ATG5 in Seminoma,” Translational Andrology and Urology 10, no. 4 (2021):1711–1722.

[30] S.Liu, Q.Li, G.Li, et al., “The Mechanism of m(6)A Methyltransferase METTL3-Mediated Autophagy in Reversing Gefitinib Resistance in NSCLC Cells by Β-Elemene,” Cell Death &Disease 11, no. 11 (2020):969.

[31] I.Corbeski, P. AVargas-Rosales, R. K.Bedi, et al., “The Catalytic Mechanism of the RNA Methyltransferase Mettl3,” eLife 12 (2024):RF92537.

[32] S.Oerum, M.Catala, C.Atdjian, et al., “Bisubstrate Analogues as Structural Tools to Investigate m(6)A Methyltransferase Active Sites,” RNA Biology 16, no. 6 (2019):798–808.

[33] C.Atdjian, D.Coelho, L.Iannazzo, M.Ethève-Quelquejeu, and E.Braud, “Synthesis of Triazole-Linked SAM-Adenosine Conjugates: Functionalization of Adenosine at N-1 or N-6 Position Without Protecting Groups,” Molecules 25, no. 14 (2020):3241.

[34] V.Meynier, L.Iannazzo, M.Catala, et al., “Synthesis of RNA-Cofactor Conjugates and Structural Exploration of RNA Recognition by an m6A RNA Methyltransferase,” Nucleic Acids Research 50, no. 10 (2022):5793–5806.

[35] Q.Zuo, L.Liao, Z. T.Yao, et al., “Targeting PP2A With Lomitapide Suppresses Colorectal Tumorigenesis Through the Activation of AMPK/Beclin1-Mediated Autophagy,” Cancer Letters 521 (2021):281–293.

[36] H.Zhang, H.Wang, Y.Hu, et al., “Targeting PARP14 With Lomitapide Suppresses Drug Resistance Through the Activation of DRP1-Induced Mitophagy in Multiple Myeloma,” Cancer Letters 588 (2024):216802.

[37] E.Yankova, W.Blackaby, M.Albertella, et al., “Small-Molecule Inhibition of METTL3 as a Strategy Against Myeloid Leukaemia,” Nature 593, no. 7860 (2021):597–601.

[38] Z.Wang, Y.Xing, B.Li, X.Li, B.Liu, and Y. Wang, “Molecular Pathways, Resistance Mechanisms and Targeted Interventions in Non-Small-Cell Lung Cancer,” Molecular Biomedicine 3, no. 1 (2022):42.

[39] A.Leonetti, S.Sharma, R.Minari, P.Perego, E.Giovannetti, and M.Tiseo, “Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer,” British Journal of Cancer 121, no. 9 (2019):725–737.

[40] S.Pushpakom, F.Iorio, P. A.Eyers, et al., “Drug Repurposing: Progress, Challenges and Recommendations,” Nature Reviews Drug Discovery 18, no. 1 (2019):41–58.

[41] M. F.Adasme, D.Parisi, A.Sveshnikova, and M.Schroeder, “Structure-Based Drug Repositioning: Potential and Limits,” Seminars in Cancer Biology 68 (2021):192–198.

[42] R.Würth, S.Thellung, A.Bajetto, M.Mazzanti, T.Florio, and F.Barbieri, “Drug-Repositioning Opportunities for Cancer Therapy: Novel Molecular Targets for Known Compounds,” Drug Discovery Today 21, no. 1 (2016):190–199.

[43] G.Jin and S. T. C. Wong, “Toward Better Drug Repositioning: Prioritizing and Integrating Existing Methods Into Efficient Pipelines,” Drug Discovery Today 19, no. 5 (2014):637–644.

[44] M.Harada-Shiba, K.Ikewaki, A.Nohara, et al., “Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia,” Journal of Atherosclerosis and Thrombosis 24, no. 4 (2017):402–411.

[45] A.Nohara, Y.Otsubo, K.Yanagi, et al., “Safety and Efficacy of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH): Results From the AEGR-733-301 Long-Term Extension Study,” Journal of Atherosclerosis and Thrombosis 26, no. 4 (2019):368–377.

[46] A. P. MChacra, M. C.Ferrari, V. Z.Rocha, and R. D.Santos, “Case Report: The Efficacy and Safety of Lomitapide in a Homozygous Familial Hypercholesterolemic Child,” Journal of Clinical Lipidology 13, no. 3 (2019):397–401.

[47] A.Vuorio, M. J.Tikkanen, and P. T.Kovanen, “Inhibition of Hepatic Microsomal Triglyceride Transfer Protein: A Novel Therapeutic Option for Treatment of Homozygous Familial Hypercholesterolemia,” Vascular Health and Risk Management 10 (2014):263–270.

[48] E.Ajufo and D. J. Rader, “New Therapeutic Approaches for Familial Hypercholesterolemia,” Annual Review of Medicine 69 (2018):113–131.

[49] C.Stefanutti, “Lomitapide-A Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia,” Current Atherosclerosis Reports 22, no. 8 (2020):38.

[50] B.Lee, S. J.Park, S.Lee, et al., “Lomitapide, a Cholesterol-Lowering Drug, Is an Anticancer Agent That Induces Autophagic Cell Death via Inhibiting Mtor,” Cell Death &Disease 13, no. 7 (2022):603.

[51] Y.Wang, S.Zhang, H.He, et al., “Repositioning Lomitapide to Block ZDHHC5-Dependant Palmitoylation on SSTR5 Leads to Anti-Proliferation Effect in Preclinical Pancreatic Cancer Models,” Cell Death Discovery 9, no. 1 (2023):60.

[52] C.Wang, M.Sun, C.Shao, et al., “A Multidimensional Atlas of Human Glioblastoma-Like Organoids Reveals Highly Coordinated Molecular Networks and Effective Drugs,” NPJ Precision Oncology 8, no. 1 (2024):19.

[53] Y.Cai, R.Feng, T.Lu, X.Chen, X.Zhou, and X. Wang, “Novel Insights Into the m(6)A-RNA Methyltransferase METTL3 in Cancer,” Biomarker Research 9, no. 1 (2021):27.

[54] C.Ma, R. J.Ma, K.Hu, et al., “The Molecular Mechanism of METTL3 Promoting the Malignant Progression of Lung Cancer,” Cancer Cell International 22, no. 1 (2022):133.

[55] D.Jin, J.Guo, Y.Wu, et al., “m(6)A mRNA Methylation Initiated by METTL3 Directly Promotes Yap Translation and Increases Yap Activity by Regulating the MALAT1-miR-1914-3p-YAP Axis to Induce Nsclc Drug Resistance and Metastasis,” Journal of Hematology &Oncology 14, no. 1 (2021):32.

[56] Y.Sun, W.Shen, S.Hu, et al., “METTL3 Promotes Chemoresistance in Small Cell Lung Cancer by Inducing Mitophagy,” Journal of Experimental &Clinical Cancer Research 42, no. 1 (2023):65.

[57] A.Dolbois, R. K.Bedi, E.Bochenkova, et al., “1, 4, 9-Triazaspiro[5.5]undecan-2-One Derivatives as Potent and Selective METTL3 Inhibitors,” Journal of Medicinal Chemistry 64, no. 17 (2021):12738–12760.

[58] F.Errani, A.Invernizzi, M.Herok, et al., “Proteolysis Targeting Chimera Degraders of the METTL3-14 m(6)A-RNA Methyltransferase,” JACS Au 4, no. 2 (2024):713–729.

[59] R. K.Bedi, D.Huang, Y.Li, and A.Caflisch, “Structure-Based Design of Inhibitors of the m(6)A-RNA Writer Enzyme METTL3,” ACS Bio &Med Chem Au 3, no. 4 (2023):359–370.

[60] E. J.Tucker, B. F. J. Wanschers, R.Szklarczyk, et al., “Mutations in the UQCC1-Interacting Protein, UQCC2, Cause Human Complex III Deficiency Associated With Perturbed Cytochrome B Protein Expression,” PLoS Genetics 9, no. 12 (2013):e1004034.

[61] L. P.Ferreira, V. M.Gaspar, and J. F.Mano, “Bioinstructive Microparticles for Self-Assembly of Mesenchymal Stem Cell-3D Tumor Spheroids,” Biomaterials 185 (2018):155–173.

[62] H.Wang, X.Du, W.Liu, et al., “Combination of Betulinic Acid and EGFR-TkIs Exerts Synergistic Anti-Tumor Effects Against Wild-Type EGFR NSCLC by Inducing Autophagy-Related Cell Death via EGFR Signaling Pathway,” Respiratory Research 25, no. 1 (2024):215.

[63] T.Tang, H.Liang, W.Wei, et al., “Aloperine Targets Lysosomes to Inhibit Late Autophagy and Induces Cell Death Through Apoptosis and Paraptosis in Glioblastoma,” Molecular Biomedicine 4, no. 1 (2023):42.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm - Oncology published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).